arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

download Export Data

Aprea Therapeutics, Inc.

APRE

$0.64 ▲ +0.04 (+6.32%) at close

10 Visible periods

18 Metrics

Peer-ranked Benchmarks

Price Chart

Health

Poor

Bearish

auto_awesome

Analytical Summary

Aprea Therapeutics, Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $4.2M

Dividend Yield —

Revenue Growth —

Op. Margin —

ROIC -84.0% ↘

FCF / Share $-1.97 ↗

Trailing P/E —

Price / Book 0.4x

FCF Yield —

Debt / Equity —

info Valuation on last close. End-of-day price, Aug 7, 2026.

10-Year Financial Trajectory

Annual

Metric Value Trend Year over Year Percentile

Net Income Profit after all expenses

$-12.60M

↑ +2.8% —

FCF / Share Free cash flow per share

$-1.97

↑ +19.9% —

trending_up

Bullish Indicators

No bullish signals detected.

warning

Bearish Risks

Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns ↓

Cash Quality →

Financial view

Statement lens

Choose the reporting cadence, isolate a period range, or search directly for a metric.

Cadence

Annual Quarterly

Range

→

📈 Is growth accelerating? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2016 10-K ↗
EPS Growth YoY (%)	17.9% Good ↑ Good Improving Year-over-year change in earnings per share Optimal: > 10%	40.5% Excellent ↑ Excellent Improving Year-over-year change in earnings per share Optimal: > 10%	94.2% Excellent ↑ Excellent Improving Year-over-year change in earnings per share Optimal: > 10%	-94.9% Weak Weak Year-over-year change in earnings per share Optimal: > 10%	31.1% Excellent Excellent Year-over-year change in earnings per share Optimal: > 10%	—	—	—	—	—
Net Income Growth YoY (%)	2.8% Caution ↑ Caution Improving Year-over-year change in net income	9.3% Fair ↑ Fair Improving Year-over-year change in net income	87.3% Excellent ↑ Excellent Improving Year-over-year change in net income	-203.4% Weak ↓ Weak Declining Year-over-year change in net income	30.6% Excellent ↑ Excellent Improving Year-over-year change in net income	-90.6% Weak ↓ Weak Declining Year-over-year change in net income	-80.7% Weak Weak Year-over-year change in net income	-2.2% Weak Weak Year-over-year change in net income	—	—
FCF Growth YoY (%)	19.9% Good ↓ Good Declining Year-over-year change in free cash flow	27.4% Excellent ↓ Excellent Declining Year-over-year change in free cash flow	77.5% Excellent ↑ Excellent Improving Year-over-year change in free cash flow	57.4% Excellent Excellent Year-over-year change in free cash flow	10.5% Fair Fair Year-over-year change in free cash flow	—	—	—	—	—

💰 Are margins durable? 1 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2016 10-K ↗
FCF / Net Income (x)	1.02x Fair ↑ Fair Improving Free cash flow relative to reported net income Optimal: > 1x	1.05x Fair ↑ Fair Improving Free cash flow relative to reported net income Optimal: > 1x	0.86x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	0.22x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	1.02x Fair ↑ Fair Improving Free cash flow relative to reported net income Optimal: > 1x	0.78x Caution ↓ Caution Declining Free cash flow relative to reported net income Optimal: > 1x	0.95x Caution → Caution Stable Free cash flow relative to reported net income Optimal: > 1x	0.98x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	0.92x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	—

🎯 Is capital allocation efficient? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2016 10-K ↗
Return on Invested Capital (%)	-84.0% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-58.6% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-72.1% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	-349.3% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	—	—	—	—	—	—
Return on Capital (%) (%)	-83.1% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-59.7% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-68.3% Weak Weak Operating profit relative to total assets Optimal: > 10%	-376.0% Weak Weak Operating profit relative to total assets Optimal: > 10%	—	—	—	—	—	—
Return on Common Equity (%) (%)	-101.3% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-775%)	-67.1% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-547%)	-84.3% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-662%)	—	-75.0% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-600%)	-69.1% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-561%)	-22.6% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-251%)	30.2% Excellent Excellent Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+101%)	42.5% Excellent Excellent Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+183%)	—

⚖️ Is the balance sheet risky? 1 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2016 10-K ↗
Net Debt (USD)	$-14.60M	$-22.85M	$-21.61M	$-28.79M	$-53.08M	$-89.02M	$-130.09M	$-65.68M	—	—

📊 What does each share earn? 5 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2016 10-K ↗
Basic EPS, GAAP (USD)	$-1.93	$-2.35	$-3.95	$-67.99	$-34.88	$-50.60	—	—	—	—
Free Cash Flow per Share (USD)	$-1.97	$-2.46	$-3.39	$-15.09	$-35.41	$-39.58	—	—	—	—
Book Value per Share (USD)	$1.52	$3.52	$4.54	$9.66	$45.30	$73.06	$118.20	$-890.39	—	—
Tangible Book Value per Share (USD)	$1.52	$3.52	$4.54	$9.66	$45.30	$73.06	$118.20	$-890.39	—	—
Basic Weighted Avg Shares (shares)	6.54M	5.51M	3.62M	1.66M	1.06M	1.06M	—	—	—	—

🏦 How resilient is the balance sheet? 2 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2016 10-K ↗
Working Capital (USD)	$12.80M	$20.22M	$18.14M	$26.95M	$49.27M	$77.09M	$123.98M	$61.13M	—	—
Total Equity (USD)	$12.44M	$19.31M	$16.95M	$25.64M	$49.51M	$77.40M	$124.24M	$-51.44M	$-35.77M	$-21.47M

📋 What is driving earnings? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2016 10-K ↗
Depreciation Expense (USD)	$21.71K	$22.32K	$7.05K	$4.40K	$12.83K	$28.83K	$11.13K	$8.32K	$7.93K	—
Net Income, GAAP (USD)	$-12.60M	$-12.96M	$-14.29M	$-112.66M	$-37.13M	$-53.48M	$-28.06M	$-15.53M	$-15.19M	—
Operating Cash Flow (USD)	$-12.89M	$-13.56M	$-12.18M	$-25.01M	$-37.69M	$-41.80M	$-26.71M	$-15.25M	$-14.00M	—

⌨️ Keyboard Shortcuts

/ Search

Esc Clear

A Annual

Q Quarterly

1-7 Jump to category

R Reset

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 10 years · 35 quarters

Aprea Therapeutics, Inc.

Analytical Summary

10-Year Financial Trajectory

Bullish Indicators

Bearish Risks

Health Breakdown

Statement lens

Benchmark Lens

Signals

Percentile Rankings

Peer Comparison

Compare APRE with peers